Introduction {#s1}
============

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common adult leukemia in the western world. Most CLL cells are inert and arrested in G0/G1 of the cell cycle. However, it is the progressive accumulation of tumor cells that ultimately leads to symptomatic disease. Pathogenic mechanisms involve multiple external events (for instance, microenvironmental and antigenic stimuli) and internal events (genetic and epigenetic) [@pone.0038158-DalBo1] that are associated with the transformation, progression and evolution of CLL.

CLL is a heterogeneous disease. Some patients progress rapidly and have short survival, whereas others have a more stable clinical course that may not need treatment for years.

Previous studies have demonstrated that overexpression of genes belonging to the B-cell receptor (BCR) pathway, and regulators, such as CD79B, BTK, TNFRSF7 (CD27), IKB2 and SYK, are correlated with a more aggressive behavior in CLL [@pone.0038158-Rodriguez1], [@pone.0038158-Rodriguez2], [@pone.0038158-Juszczynski1], [@pone.0038158-Aggarwal1]. Along with this finding, oncogenic mutations in multiple genes such as CARD11 [@pone.0038158-Lenz1], LYN [@pone.0038158-Contri1] and A20 [@pone.0038158-Shembade1], among others, are described as causing deregulation in the BCR and related pathways, such as NFkB in B-cell lymphoma.

Several lines of evidence coincide in revealing that stimulatory and growth signals delivered by BCR and co-receptors enable lymphoma cells to avoid apoptosis and so to proliferate, thereby constituting the driving force for B-cell survival. These seem to be common features of lymphoma pathogenesis. It has been proved that maintained signaling mediated via this pathway is an essential mechanism for tumor cell survival in some lymphoma types, such as CLL and diffuse large B-cell lymphoma (DLBCL) [@pone.0038158-Stevenson1], [@pone.0038158-Ke1], [@pone.0038158-Davis1]. However, the molecular mechanism responsible for the activation has not been fully clarified. On the basis of the hypothesis that BCR activation may depend on somatic mutations of the BCR genes and related pathways [@pone.0038158-Compagno1], we have used deep sequencing technology to investigate the existence of changes in the coding and regulatory sequences of a selection of 301 genes that are associated with BCR, or related to signaling from the B-cell receptor, such as the NFKB and JAK/STAT pathways.

Results {#s2}
=======

Clinical data of the 10 patients included in the study are shown in [Table 1](#pone-0038158-t001){ref-type="table"}. It is a heterogeneous group of patients in terms of staging, genetic alterations and prognostic. Four of the patients showed progressive diseases, which is defined as the need for therapy, while stable disease is defined as those cases that do not require therapy.

10.1371/journal.pone.0038158.t001

###### Clinical features, evolution and biological characteristics of the ten CLL patients studied.

![](pone.0038158.t001){#pone-0038158-t001-1}

  Samples    Follow-up (months)   Rai/Binet at diagnosis   Rai/Binet current stage      Cytogenetic alterations      Lymphocytes (µl)   CD19/CD5 (%)    ZAP-70    CD38 (%)   Rearrangement   IGHV homology   β2 microglobulin   LDH
  --------- -------------------- ------------------------ ------------------------- ------------------------------- ------------------ -------------- ---------- ---------- --------------- --------------- ------------------ ------
  CLL1              102                    A/0                       A/I                      Trisomy 12                  85,000             92        POSITIVE     12.5        IGVH1-2           100              1.4          417
  CLL2               12                    A/0                 A/0 progressive             Rearrangement IgH             180,000             90        POSITIVE     14.4       IGHV3-11          99.6             12.5\*        403
  CLL3              108                    A/I                       A/I                        del13q                    55,000             80        NEGATIVE     3.9         IGHV1-2          94.3              1.4          325
  CLL4              134                    A/0                       A/I                        del13q                    40,000             90        NEGATIVE     0.2         IGHV2-5          96.4              1.6          315
  CLL5              1.5                    B/II               B/II progressive       del17p13, c-myc amplification       170,000             94        POSITIVE     15.4       IGHV2-70          99.5              5.1          1044
  CLL6               9                     B/II                     B/II                        del13q                    17,400             80        POSITIVE      0         IGHV3-21          98.6              1.7          523
  CLL7               16                    B/II               B/II progressive                Trisomy 12                  53,000             93        POSITIVE      13        IGHV1-69          99.2              1.8          491
  CLL8               34                    A/0                       A/0                    del13q, del11q                10,300             62        NEGATIVE     5.4           DH              ND               2.1          321
  CLL9              108                    A/0                C/III progressive                 del13q                   171,000             96        NEGATIVE     0.1        IGHV3-21          92.8              2.2          572
  CLL10              60                    A/I                       A/I                        del13q                    22,000             82        NEGATIVE     4.5        IGHV1-69           100              1.4          423

Summary of the prognosis factors considered in the clinic and genetic lesions that the ten patients harbor. ND = not done, del = deletion.

FISH analysis revealed a variety of cytogenetic abnormalities, including del(13q), del(17p), del(11q) and trisomy 12. The most frequent of these was del(13q), which was found in 6 of the 10 samples.

To explore whether BCR activation depends on somatic mutations in BCR-signaling genes and related pathways, we used single-end deep sequencing to perform a mutational screening of the exonic and regulatory regions of 301 selected genes ([Table S1](#pone.0038158.s004){ref-type="supplementary-material"}). The study pipeline and DNA sequencing data, including QC metrics, are summarized in [Figure S1](#pone.0038158.s001){ref-type="supplementary-material"} and [Table S2](#pone.0038158.s005){ref-type="supplementary-material"}.

In summary, detected variants were ranked by their VCF QUAL parameter and manually reviewed in the IGV browser (<http://www.broadinstitute.org/igv/>). The percentage of reads supporting the mutation of the total number of reads at a given position was taken as \>20% with a minimum depth of 30× in tumor DNA, and \<0.5% in normal DNA [@pone.0038158-Jones1]. Selected candidates (non-synonymous, nonsense or frameshift mutations, or that affecting intronic or UTR regions) were validated by PCR amplification of the genomic region and capillary sequencing ([File S1](#pone.0038158.s003){ref-type="supplementary-material"}). Seven variants were selected for validation, and all of them were validated by capillary sequencing ([Table 2](#pone-0038158-t002){ref-type="table"} and [Figure 1](#pone-0038158-g001){ref-type="fig"}).

![Mutation validation.\
Capillary sequencing chromatograms confirming the seven putative variants. *KRAS*, *SMARCA2*, *PRKD3*, *STAT6*, *LIFR* and *ILB1* showed one point mutation each, depicted as two peaks in the tumoral DNA chromatogram. For *NFKBIE*, the 4-bp deletion was also confirmed. NT = non-tumoral, TM = tumoral. R = A or G; Y = C or T; S = C or G; K = T or G; /..../ = 4-bp deletion.](pone.0038158.g001){#pone-0038158-g001}
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###### Validated somatic mutation.

![](pone.0038158.t002){#pone-0038158-t002-2}

  Samples    Position (hg19)   Description        Substitution         Region       SNV Type      Prediction   Gene Name
  --------- ----------------- ------------- ------------------------ ---------- ---------------- ------------ -----------
  CLL2       chr5: 38478732        G-a                 NA              3′UTR       Non-coding         NS         LIFR
  CLL5        chr6:44232738       -GTAA      Frame-shift (253--254)   Exon CDS   Non-synonymous   Truncated     NFKBIE
  CLL5       chr2:113590942        G-t                 NA             Intronic     Non-coding         NS         IL1B
  CLL7       chr12:57493232        G-c                 NA             Intronic     Non-coding         NS         STAT6
  CLL7       chr12:25380279      GGT-GaT              G60D            Exon CDS   Non-synonymous    Damaging      KRAS
  CLL7        chr9:2182166       CGG-CaG             R1462Q           Exon CDS   Non-synonymous    Damaging     SMARCA2
  CLL9        chr2:37505118      AAT-AgT             N396S            Exon CDS   Non-synonymous   Tolerated      PRKD3

CDS: Coding sequence. NA: not annotated. Chr: chromosome.

Three of these mutations (present in *KRAS*, *SMARCA2* and *PRKD3* genes) were non-synonymous point mutations, located in the coding region of the genes. Two were G\>A transitions and one was an A\>G change. There was also a frame-shift mutation due to a 4-bp deletion (in *NFKBIE* gene) that resulted in a stop codon 13 aminoacids downstream from it, which would generate a truncated protein. The Ensembl Variant Effect Predictor (VEP) [@pone.0038158-McLaren1] predicted that mutations in two of the genes (*KRAS* and *SMARCA2*) were deleterious to protein function ([Figure 2](#pone-0038158-g002){ref-type="fig"} and [Table 2](#pone-0038158-t002){ref-type="table"}).

![Schematic representation of the mutated proteins with the primary structural domains highlighted.](pone.0038158.g002){#pone-0038158-g002}

The mutation in SMARCA2 lies inside the bromodomain of the protein. Using the NMR structure of the bromodomain (PDB code 2DAT, chain A) we were able to check that the WT residue is placed in one of the loops of the bromodomain, opposite to the region of the helical bundle involved in the binding with the acetyl-lisine, and so the effect of this mutation is difficult to predict (data not shown).

Finally, there were two point mutations located at intronic sites (*STAT6* and *ILB1*) and one in the 3′ UTR (*LIFR*).

Mutations in coding sequences were detected in the 3 cases with a progressive course. CLL7 and CLL5 (with 2 and 1 different mutations, respectively) exhibited adverse prognosis factors, such as unmutated IGVH (IGHV1-69 and IGHV2-70, respectively) and ZAP-70 positivity; case CLL5 also harbor 17p13 deletion and c-myc amplification. Case CLL9 progressed from stage RAI-BINET A/0 at diagnosis to C/III. This case harbors del(13q) and mutated IGVH3-21, a finding usually associated with a poor prognosis, irrespective of the IGVH mutational status [@pone.0038158-Thorselius1] ([Table 1](#pone-0038158-t001){ref-type="table"}).

Discussion {#s3}
==========

Based on the hypothesis that BCR activation may depend on somatic mutations of the BCR and related pathways we have performed a complete mutational screening of 301 selected genes associated with BCR signaling and related pathways, such as NFkB, using massive parallel sequencing technology in 10 CLL cases. Three out of four progressive cases included in the study have mutated genes in the coding region. The mutated genes were *KRAS*, *SMARCA2*, *NFKBIE and PRKD3*, all of which play a role in BCR, NFkB and related signaling pathways.

The KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) protein is a GDP/GTP-binding protein that acts as an intracellular signal transducer, a molecular regulator in a variety of signal transduction pathways, such as BCR signaling pathways ([Figure S2](#pone.0038158.s002){ref-type="supplementary-material"}), or controlling phenomena such as cytoskeleton integrity, proliferation differentiation, adhesion, cell migration and apoptosis. From 17 to 25% of all human tumors have the activating *KRAS* mutation, but it has been described in the hematopoietic and lymphoid tissue of only about 5% of cases (COSMIC database; <http://www.sanger.ac.uk/genetics/CGP/cosmic/>). Specifically in CLL, *KRAS* mutations have been described only exceptionally [@pone.0038158-Nedergaard1], [@pone.0038158-Gougopoulou1]. The mutation identified here, located at codon 60, has not been described before, but is located in the hotspot region of codons 59, 61 and 62. Therefore, the putative effect of this mutation on protein function should be similar, leading to the activation of the protein.

NFKBIE (nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor epsilon) is upregulated following NF-κB activation. NFKBIE is able to inhibit NF-κB-directed transactivation via cytoplasmic retention of REL proteins. For *NFKBIE*, inactivating mutations have been described in Hodgkin/Reed-Sternberg cells [@pone.0038158-Emmerich1]. In the paper by Quesada et al.[@pone.0038158-Quesada1] a non-sense mutation in a CLL case is also described (chr6: 44230329; C/A) and in the COSMIC database, two mutations are described in breast cancer, one of which is a nonsense mutation, like the one described here. This kind of mutation should give rise to a truncated protein without the ankyrin motif mediating the protein--protein interaction and would eventually be degraded. The inactivation of NFKBIE by mutation would lead to the sustained activation of the NFKB pathway ([Figure S2](#pone.0038158.s002){ref-type="supplementary-material"}), which has previously been linked to CLL pathogenesis [@pone.0038158-Herreros1]

SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2), also known as SNF2L2 or BRM, is part of the large ATP-dependent chromatin remodeling complex SWI/SNF, which is required for transcriptional activation of genes normally repressed by chromatin. It has been described as a mediator of NFkB transcriptional activation, and is also associated with BCR signaling mediated by BTK [@pone.0038158-Hirano1], [@pone.0038158-Tando1]. ([Figure S2](#pone.0038158.s002){ref-type="supplementary-material"}). Four substitution mutations are reported for the *SMARCA2* gene in the COSMIC database and in the ICGC portal (<http://dcc.icgc.org/>); two mutations were identified and validated in CLL (intronic) and glioblastoma (non-synonymous coding). The mutation found in the present study is located in the bromodomain, whose function is not completely clear although it may play a role in the assembly or activity of multi-component complexes involved in transcriptional activation. Mutations have been described in other members of the same family, such as *ARID1A* in around 50% of ovarian clear cell carcinomas and in gastric cancer [@pone.0038158-Jones1], [@pone.0038158-Wiegand1], [@pone.0038158-Wang1], and *SMARCA4/BRG1* in lung tumors [@pone.0038158-RodriguezNieto1], [@pone.0038158-Medina1]. In both cases, mutations are located throughout the entire gene coding sequence.

PRKD3 (protein kinase D3) belongs to the protein kinase C family of serine- and threonine-specific protein kinases that can be activated after BCR engagement [@pone.0038158-Pracht1] by calcium and the second messenger, diacylglycerol ([Figure S2](#pone.0038158.s002){ref-type="supplementary-material"}). It phosphorylates a wide variety of protein targets and is involved in diverse cellular signaling pathways [@pone.0038158-Haxhinasto1]. Only sporadic mutations have been described in the *PRKD3* gene in lung adenocarcinoma, ovary and brain glioma (COSMIC and ICGC databases).

The other mutations found in *STAT6*, *IL1B* and *LIFR*, are located in intronic regions and their consequences are therefore not clear.

Recently, several groups have identified mutations in CLL using exome sequencing [@pone.0038158-Quesada1], , *NOTCH1* being the most frequently mutated gene that behaves as an independent predictor of poor survival [@pone.0038158-Fabbri1]. Other mutated genes identified in these studies were *SF3B1* [@pone.0038158-Quesada1], [@pone.0038158-Wang2], *MYD88*, *KLHL6* and *XPO1* [@pone.0038158-Puente1], *TP53*, *PLEKHG5*, *TGM7* and *BIRC3* [@pone.0038158-Fabbri1].

Given the small number of patients included in the series, this study is unable to conclude statistical significance. To infer a possible role and relevance for each mutated gene described, they need to be validated in a larger series of patients and through functional studies. Nevertheless, the findings are consistent with the idea that, at least partially, BCR and NFkB signaling and related pathways in CLL cells could depend on somatic mutations.

In conclusion, this study identifies new genes mutated in CLL and demonstrates that next-generation sequencing technologies applied to selected genes or pathways of interest are powerful tools for identifying novel mutational changes.

Materials and Methods {#s4}
=====================

1. Clinical samples {#s4a}
-------------------

The current study was approved by the institutional Ethics Committee of the "Instituto de Salud Carlos III" (CEI PI 03_2011). Fresh blood samples from 10 untreated CLL patients were obtained from Hospital Universitario Puerta de Hierro-Majadahonda, with the collaboration of the CNIO Tumour Bank, in adherence with the protocols of the Ethics Committee of the Instituto de Salud Carlos III. All patients involved gave written informed consent for their participation in the study. Clinical data were collected according to the criteria of the National Cancer Institute (NCI) Working Group [@pone.0038158-Cheson1].

Tumoral DNA was collected from peripheral blood cells, CD19+ B-cell, then purified using the RossetteSep Human B cell enrichment kit (StemCell Technologies) or an immunomagnetic purification process (Myltenyi Biotec). Tumor cell purity was taken to be the ratio CD19/CD3, which was measured by FACS. The tumor B-cell purity of CLL samples after purification ranged from 88.00 to 99.80%. Non-tumoral DNA from each patient was collected from oral mucosa samples.

DNA was extracted by the phenol--chloroform method and the quality and quantity of purified DNA was assessed by fluorometry (Qubit, Invitrogen) and gel electrophoresis.

2. Target enrichment and sequencing {#s4b}
-----------------------------------

### Gene selection and bait design {#s4b1}

To select genes we browsed the KEGG and BioCarta databases and previously published data on CLL and genes acting on BCR signaling and related pathways, such as NFkB and JAK/STAT [@pone.0038158-Rodriguez1],[@pone.0038158-Rodriguez2],[@pone.0038158-Davis1],[@pone.0038158-Compagno1],[@pone.0038158-Herreros1] ([Table S1](#pone.0038158.s004){ref-type="supplementary-material"}).

The USCS Genome Browser (<http://genome.ucsc.edu/>) was used to select exonic sequences. A region 200 bp downstream of the start transcription point was also included. The coordinates of the genomic sequences were based on UCSC hg19.

The web-based design tool eArray (Agilent Technologies Inc, Santa Clara, CA, USA) was used to design the baits for the SureSelect Target Enrichment System kit.

Biotinylated-RNA 120-mer capture probes had sequences complementary to those of the selected regions, and extended 20 bp upstream and downstream of each region. Repeat masked regions were avoided in the design. The targeted region was 1.36 Mbp (up to 0.04% of the human genome), thereby consisting of 4,000 exons and 580 ds regions. 35,985 capture-centered probes were designed, allowing an overlap of 60 bp and a 4× tiling frequency. The average tiling frequency achieved was 3.2×, because exons shorter than 120 bp had a unique complementary probe.

Selected sequences were enriched for each library using the SureSelect custom design Kit (Agilent Technologies).

### Library preparation and sequencing {#s4b2}

The protocol for "SureSelect Target Enrichment System" kit (Agilent Technologies) combined with the "Genomic DNA Sample Prep for single-end sequencing" guide (Illumina, San Diego, CA, USA) were used for sample sequence enrichment (31) and library preparation. Briefly, 1--3 µg of high molecular weight genomic DNA from each sample was fragmented by acoustic shearing on a Covaris S2 instrument. Fractions of 150--300 bp were ligated to Illumina\'s adapters and PCR-amplified for 6 cycles. Exon Enrichment: 300 ng of whole library were hybridized to SureSelect Oligo Capture kit for 24 h at 65°C. Biotinylated hybrids were captured, and the enriched libraries were completed with 12 cycles of PCR. The resulting purified DNA library was applied to an Illumina flow cell for cluster generation and sequenced using the Illumina Genome Analyzer IIx for 36 bases in a single-read format by following the manufacturer\'s protocols.

3. Data analysis {#s4c}
----------------

### Alignment, mapping and identification of somatic variants {#s4c1}

Sequencing data were first checked by FastQC (<http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/>) for quality control checks on raw sequence data and then aligned to the human reference genome (GRCh37) using Burrows-Wheeler alignment (BWA). That reads unmapped by BWA [@pone.0038158-Li1] were realigned using BFAST [@pone.0038158-Homer1]. Somatic variants were identified using the Unified Genotyper v2 available at the GATK [@pone.0038158-DePristo1]. For variant calling we used GATK Unified Genotyper v2 applying the "Discovery" genotyping mode and default parameters for filtering. Thus, SNPs available at dbSNP 132 (hg19) and those reported by the 1000 Genomes Project were filtered out from VCF output files. The GATK QUAL field was employed for ranking selected somatic variants. The percentage of reads supporting the mutation of the total number of reads at a given position was taken as \>20% in the tumor DNA, and \<0.5% in normal DNA [@pone.0038158-Jones1]. Only those variants showing a depth 30× in tumoral samples, were considered for validation. Data has been deposited in the Sequence Read Archive (SRA) database (<http://www.ncbi.nlm.nih.gov/sra>) (SRA049097).

Biological impact predictions for detected variants were obtained from Ensembl Variant Effect Predictor (VEP: <http://www.ensembl.org/tools.html>) [@pone.0038158-McLaren1].

Supporting Information {#s5}
======================

###### 

**Workflow.** The USCS Genome Browser (<http://genome.ucsc.edu/>) was used to select exonic sequences and the web-based design tool eArray (Agilent Technologies) was used to design the baits for the SureSelect Target Enrichment System kit. The library was prepared and sequenced in a GA2 sequencer from Illumina. Sequencing data were aligned to the human reference genome (GRCh37) using Burrows-Wheeler alignment (BWA) and BFAST. Somatic variants were identified using the Unified Genotyper v2 available at the GATK. Somatic variants were filtered by i) known SNPs available at dbSNP 132 (hg19) and those reported by 1000 Genome Project, ii) changes present in the matched germinal DNA and iii) synonymous changes. Ensemble VEP was used to predict biological effect and, finally the variants were ranked by GATK quality score, manually reviewed and validated by capillary sequencing.
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Click here for additional data file.
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**Mutations in components of B-cell receptor signaling pathways.** A modified KEGG (<http://www.genome.jp/kegg/>) pathway including B-cell receptor signaling is depicted. Somatically mutated genes in CLL are highlighted in red.
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Click here for additional data file.
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**Supplementary Materials and Methods: Validation and sequencing.**

(DOC)
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Click here for additional data file.

###### 

**List of sequenced genes.** 301 genes, belonging to the BCR, NFkB and JAK/STAT signaling pathways, were selected for sequencing.

(XLS)
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Click here for additional data file.

###### 

**Quality control.** Quality metrics of alignment, mapping and coverage depth from the two independent experiments. Mbp: Megabase pair. T: Tumoral. NT: Non-tumoral.

(XLS)

###### 

Click here for additional data file.
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